Key Insights

Highlights

Treatment Research

3 treatments under study, led by Loncastuximab Tesirine

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Unknown1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07197307Phase 2Recruiting

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

SYFf779be00ec8d4fc48281cc340b3e922aPhase 2Unknown

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Showing all 2 trials

Research Network

Common Treatments

  • Loncastuximab Tesirine2
  • Epcoritamab2
  • Loncastuximab Tesirine And Epcoritamab1

Active Sponsors

  • Universität Münster1
  • Universitaet Muenster1
  • AbbVie1
  • Sobi, Inc.1

Related Conditions

  • Highgrade Bcell Lymphoma Hgbl2
  • Aggressive Diffuse Large Bcell Lymphoma1
  • Diffuse Large Bcell Lymphoma Dlbcl1

Activity Timeline